148 related articles for article (PubMed ID: 38378431)
1. SCGB2A2 as a predictor of prognosis and response to immune-checkpoint blockage in metastatic triple-negative invasive breast cancer.
Zheng Y; Peng Y
Asian J Surg; 2024 May; 47(5):2299-2301. PubMed ID: 38378431
[No Abstract] [Full Text] [Related]
2. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
3. Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.
Wang C; Feng G; Zhu J; Wei K; Huang C; Wu Z; Yu Y; Qin G
Future Oncol; 2022 Mar; 18(9):1055-1066. PubMed ID: 35105171
[No Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Heeke AL; Tan AR
Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
7. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
Dusenbery AC; Maniaci JL; Hillerson ND; Dill EA; Bullock TN; Mills AM
Am J Surg Pathol; 2021 May; 45(5):701-707. PubMed ID: 33739790
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
9. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
Jarroudi OA; Bairi KE; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
[TBL] [Abstract][Full Text] [Related]
10. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
11. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
He R; Yuan X; Chen Z; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
[TBL] [Abstract][Full Text] [Related]
12. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
16. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
Katuwal NB; Park N; Pandey K; Kang MS; Hong SD; Ghosh M; Kim SG; Cho YB; Hur J; Kim SK; Moon YW
Anticancer Res; 2023 Jan; 43(1):85-95. PubMed ID: 36585194
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
19. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]